Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to Korean children receiving routine pediatric vaccines

Pediatric Infectious Disease Journal

Volumn 32, Issue 3, 2013, Pages 266-273

  Kim, Dong Soo ^a   Shin, Seon Hee ^b   Lee, Hoan Jong ^c   Hong, Young Jin ^d   Lee, Soo Young ^e   Choi, Kyong Min ^f   Oh, Chi Eun ^g   Kim, Ki Hwan ^a   Juergens, Christine ^h   Patterson, Scott ^h   Giardina, Peter C ^h   Gruber, William C ^h   Emini, Emilio A ^h   Scott, Daniel A ^h  

^a Yonsei University College of Medicine   (South Korea)

^b Hallym University Medical Center   (South Korea)

^c Seoul National University Children's Hospital   (South Korea)

^d Inha University Hospital   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Catholic Kwandong University   (South Korea)

^g Kosin University College of Medicine   (South Korea)

^h PFIZER INC   (United States)

Author keywords

13 valent pneumococcal conjugate vaccine; Immunogenicity; Korea; Pediatric; Safety

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; KOREA; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTICENTER STUDY; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SKIN REDNESS; VACCINATION;

ANTIBODIES, BACTERIAL; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; DRUG TOXICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; KOREA; MALE; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 84876298224     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182748bb6     Document Type: Article

References (38)

1. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Record. 2007;82: 93-104.
2. Cho HK, Lee H, Kang JH, et al. The causative organisms of bacterial meningitis in Korean children in 1996-2005. J Korean Med Sci. 2010;25: 895-899.
3. Eun BW, Kim SJ, Cho EY, et al. Genetic structure of Streptococcus pneumoniae isolated from children in a tertiary care university hospital, in Korea, 1995 to 2005. Diagn Microbiol Infect Dis. 2010;68:345-351.
4. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenic-ity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
5. Eskola J, Kilpi T, Palmu A, et al.; Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
6. Pilishvili T, Lexau C, Farley MM, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
7. Choi EH, Kim SH, Eun BW, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerging Infect Dis. 2008;14:275-281.
8. World Health Organization Expert Committee on Biological Standardization. Recommendations to assure the quality, safety, and efficacy of pneumococcal conjugate vaccines. 2009. Available at: http://www.who.int/biologicals/areas/ vaccines/pneumo/Pneumo-final-23 APRIL-2010.pdf Accessed December 12, 2012.
9. Quataert SA, Kirch CS, Wiedl LJ, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol. 1995;2:590-597.
10. Quataert SA, Rittenhouse-Olson K, Kirch CS, et al. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(F). Clin Diagn Lab Immunol. 2004; 11:1064-1069.
11. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25:3816-3826.
12. Lee LH, Frasch CE, Falk LA, et al. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine. 2003;21:2190-2196.
13. Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol. 1997;4:415-422.
14. Cooper D, Yu X, Sidhu M, et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29:7207-7211.
15. Bryant KA, Block SL, Baker SA, et al.; PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010;125:866-875.
16. Chan IS, Zhang Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics. 1999;55:1202-1209.
17. Yeh SH, Gurtman A, Hurley DC, et al.; 004 Study Group. Immunogenic ity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493-e505.
18. Kieninger DM, Kueper K, Steul K, et al.; 006 study group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192-4203.
19. Snape MD, Klinger CL, Daniels ED, et al. Immunogenic ity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29:e80-e90.
20. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502.
21. Heidelberger M, Jann K, Jann B, et al. Relations between structures of three K polysaccharides of Escherichia coli and cross-reactivity in antipneumococcal sera. J Bacteriol. 1968;95:2415-2417.
22. Heidelberger M, Nimmich W Additional immunochemical relationships of capsular polysaccharides of Klebsiella and pneumococci. J Immunol. 1972;109:1137-1144.
23. Feavers I, Knezevic I, Powell M, et al.; WHO Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine. 2009;27:3681-3688.
24. Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29: 9127-9131.
25. Moore M, Link-Gelles R, Farley M, et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), U.S., 2010-2011 [poster 179]. In: 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD 8); Iguaçu Falls, Brazil; Marchl 1-15, 2012.
26. van der Linden M, von Kries R, Imöhl M. Effects of immunization with higher valent pneumococcal conjugate vaccines in German children on numbers of reported IPD cases (1997-2012) [poster 391]. In: 30th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); Thessaloniki, Greece; May 8-11, 2012.
27. Grimprel E, Laudat F, Patterson S, et al. Immunogenic ity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine. 2011;29: 9675-9683.
28. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017-1026.
29. Kim NH, Lee J, Lee SJ, et al. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar) in Korean infants: differences that are found in Asian children. Vaccine. 2007;25:7858-7865.
30. Shao PL, Lu CY, Chang LY, et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in Taiwanese infants. J Formos Med Assoc. 2004;103:613-617.
31. Shao PL, Lu CY, Chang LY, et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine booster in Taiwanese toddlers. J Formos Med Assoc. 2006;105:542-549.
32. Huang LM, Lin TY, Juergens C. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan. Vaccine. 2012;30:2054-2059.
33. Booy R, Haworth EA, Ali KA, et al. Immunogenicity of routine vaccination against diphtheria, tetanus, and Haemophilus influenzae type b in Asian infants born in the United Kingdom. Arch Dis Child. 2005;90:589-591.
34. Björkholm B, Granström M, Taranger J, et al. Influence of high titers of maternal antibody on the serologic response of infants to diphtheria vaccination at three, five and twelve months of age. Pediatr Infect Dis J. 1995;14:846-850.
35. Glezen WP Effect of maternal antibodies on the infant immune response. Vaccine. 2003;21:3389-3392.
36. Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374:1339-1350.
37. Pabst HF, Spady DW Effect of breast-feeding on antibody response to conjugate vaccine. Lancet. 1990;336:269-270.
38. Silfverdal SA, Ekholm L, Bodin L. Breastfeeding enhances the antibody response to Hib and Pneumococcal serotype 6B and 14 after vaccination with conjugate vaccines. Vaccine. 2007;25:1497-1502.